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Abstract 
Exchange protein activated by cyclic AMP (EPAC1) suppresses multiple inflammatory 
actions in vascular endothelial cells (VECs), partly due to its ability to induce expression of 
the suppressor of cytokine signalling 3 (SOCS3) gene, the protein product of which inhibits 
interleukin 6 (IL6) signalling through the JAK/STAT3 pathway. Here, for the first time, we 
use the non-cyclic nucleotide EPAC1 agonist, I942, to determine its actions on cellular 
EPAC1 activity and cyclic AMP-regulated gene expression in VECs. We demonstrate that 
I942 promotes EPAC1 and Rap1 activation in HEK293T cells and induces SOCS3 
expression and suppresses IL6-stimulated JAK/STAT3 signalling in HUVECs. SOCS3 
induction by I942 in HUVECs was blocked by the EPAC1  antagonist, ESI-09, and EPAC1 
siRNA, but not by the broad-spectrum protein kinase A (PKA) inhibitor, H89, indicating that 
I942 regulates SOCS3 gene expression through EPAC1. RNA sequencing was carried out to 
further identify I942-regulated genes in HUVECs. This identified 425 I942-regulated genes 
that were also regulated by the EPAC1-selective cyclic AMP analogue, 007, and the cyclic 
AMP-elevating agents, forskolin and rolipram (F/R). The majority of genes identified were 
suppressed by I942, 007 and F/R treatment and many were involved in the control of key 
vascular functions, including the gene for the cell adhesion molecule, VCAM1. I942 and 007 
also inhibited IL6-induced expression of VCAM1 at the protein level and blocked VCAM1-
dependent monocyte adhesion to HUVECs. Overall, I942 represents the first non-cyclic 
nucleotide EPAC1 agonist in cells with the ability to suppress IL6 signalling and 
inflammatory gene expression in VECs. 
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Introduction 
Atherosclerosis is a serious cardiovascular disease (CVD), which arises from chronic 
localised inflammation at coronary and carotid arterial branch points [1], and remains the 
principal cause of death in the developed world 
(http://www.who.int/cardiovascular_diseases/en/) despite changes in lifestyle and the 
widespread use of anti-hypertensive and lipid-lowering drugs. The increased inflammatory 
activity associated with atherosclerosis is partially brought about by increased levels of pro-
inflammatory cytokines in the circulation, particularly IL6 [2, 3], which is associated with a 
twofold increase in CVDs and mortality in elderly patients [4]. IL6 localises to 
atherosclerotic plaques [5] and promotes chronic, low-level vascular inflammation, leading to 
neointimal thickening [6], vascular dysfunction [7], hypertension [8] and increased risk of 
myocardial infarction [2]. IL6 affects vascular endothelial cells (VECs) by triggering counter-
productive angiogenesis, through vascular endothelial growth factor (VEGF) production [9], 
and increasing the secretion of chemokines, like the chemokine (C-C motif) ligand 2 (CCL2), 
also referred to as monocyte chemo-attractive protein 1 (MCP-1) [10], that recruit monocytes 
to the inflamed endothelium. Initial engagement of monocytes with the endothelium involves 
rolling adhesion mediated by E-selectin (SELE) [11, 12], followed by firm adhesion mediated 
by interactions between integrins expressed on leukocytes and adhesion molecules (ICAM1, 
VCAM1) expressed on endothelial cells [12]. Finally, cadherin molecules at adherens 
junctions mediate trans-endothelial migration of monocytes [13, 14]. 
It is IL6 receptor “trans-signalling” [15] that is thought to underlie the pro-inflammatory 
actions of IL6 in a variety of diseases, including atherosclerosis [16]. During trans-signalling, 
IL6 binds to soluble forms of the IL6 receptor  (sIL6R), allowing activation of gp130, 
even in cells that do not normally express the IL6R subunit, such as VECs [15]. Since 
gp130 is present on all cells, trans-signalling therefore dramatically increases the range of cell 
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targets for IL6 signalling to include VECs [15]. Consequently, binding of the IL6/sIL6R 
complex to gp130 on VECs leads to receptor clustering and activation of the JAK/STAT3 
and ERK, MAPK and PI3K signalling pathways. Of these, it is activated STAT3 that then 
homodimerises and translocates to the nucleus, where it acts as a transcription factor for the 
induction of pro-inflammatory IL6-responsive genes, such as CCL2/MCP1, VEGF, VCAM1, 
ICAM1 and SELE [10, 17-19]. IL6-promoted JAK/STAT3 signalling is normally 
downregulated by the suppressor of cytokine signalling (SOCS) family of proteins [20], 
which are induced by JAK/STAT3, forming a classical negative feedback loop [21]. The 
SOCS3 protein contains an SH2 domain that interacts with  JAK-phosphorylated receptors, 
thereby inhibiting JAK/STAT3 signalling [22]. SOCS3 expression is increased in 
atherosclerotic plaques [23, 24] and the importance of SOCS3 for the suppression of CVD 
has been shown by a series of knockdown experiments, which demonstrate that IL6 promotes 
acute and chronic inflammatory disease in the absence of SOCS3 [25]. Moreover, 
knockdown of SOCS3 in VECs leads to pathological angiogenesis [26] and enhanced STAT3 
activation and atherogenesis in apolipoprotein-E (apoE)-/- mice [24]. In contrast, 
overexpression of SOCS3 peptide fragments or full-length protein suppresses JAK/STAT3 
signalling and the development of atherosclerosis [27-30]. SOCS3 induction may therefore 
serve as a valid drug target for the suppression of inflammation associated with 
atherogenesis. 
The cyclic AMP sensor enzyme, EPAC1, is a logical drug target for vascular inflammation 
because its ligand-mediated activation suppresses a wide range of inflammatory actions [31-
33]. EPAC1 and EPAC2 proteins [34, 35] are cyclic AMP-regulated guanine nucleotide 
exchange factors (GEFs) that activate the Ras GTPase homologues, Rap1 and Rap2, 
independently of the classical route of cAMP signal transduction through protein kinase A 
(PKA). Rather, binding of cAMP to a specific cyclic nucleotide-binding domain (CNBD) 
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induces a conformational change in EPAC proteins that relieves auto-inhibition of the 
catalytic GEF domain [33]. EPAC1 appears to be a central controller of anti-inflammatory 
processes in VECs [31, 36]. For example, activation of EPAC1 leads to SOCS3 induction, 
blockade of IL6 JAK/STAT3 signalling and potentiation of barrier function in vitro and in 
vivo, in normal mice [36]. Moreover, activation of EPAC in cardiac myocytes attenuates the 
inhibitory effect of IL6 on cardiac function and contractility in response to isoproterenol, 
most likely through inhibition of the JAK/STAT3 signalling by SOCS3 [37]. Using high 
throughput screening (HTS) we identified a novel ligand (I942) that exhibits agonist 
properties against EPAC1, but not EPAC2. I942 interacts with the EPAC1 CNBD and 
activates EPAC1 GEF activity [33, 38]. In contrast, there was very little agonist action of 
I942 towards EPAC2 or protein kinase A (PKA) [38]. This is the first identified non-cyclic 
nucleotide small molecule with agonist properties towards EPAC1, which can be useful as an 
experimental tool to investigate the role of EPAC1 in health and disease. Our aim now is to 
obtain evidence that I942 acts as an agonist towards EPAC1 in cells and influences 
inflammatory signalling in vascular endothelial cells. 
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Materials and Methods 
Materials 
Pooled human umbilical vascular endothelial cells (HUVECs) and endothelial cell growth 
medium 2 (EGM2) were purchased from PromoCell (Heidelberg, Germany). Antibodies to 
EPAC1 (5D3), Rap1, phospho-CREB (Ser 133), STAT3/phospho-STAT3 (Tyr 705), 
ICAM1, VCAM1 and GAPDH were obtained from New England Biolabs UK Ltd 
(Hertfordshire, UK). Antibodies to E-selectin (SELE) were from Bio-Techne (Abingdon, 
UK). Anti-SOCS-3 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). SuperSignal™ West Pico Chemiluminescent Substrate was from Fisher Scientific 
(Loughborough, UK). Secondary antibodies, anti-rabbit-IgG horseradish peroxidase, anti-
goat-IgG horseradish peroxidase and anti-mouse-IgG horseradish peroxidase conjugates, 
were from Sigma-Aldrich Company Ltd. (Dorset, England). Forskolin, rolipram and N-
benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132) were obtained from Calbiochem 
(Paisley, UK), whereas H-89 was from Sigma-Aldrich, UK. The EPAC1-selective cyclic 
AMP analogue, 8-pCPT-2′-O-Me-cAMP (007), and the EPAC1 antagonist, ESI-09, were 
purchased from Biolog Life Sciences Institute (Bremen, Germany). I942 (N-(2,4-
dimethylbenzenesulfonyl)-2-(naphthalen-2-yloxy)acetamide) was purchased from MolPort 
(Riga, Latvia). Adrenomedullin 2/intermedin (ADM2) was from the Peptide Institute (Osaka, 
Japan). Recombinant human interleukin 6 (IL6) protein and recombinant human soluble IL6 
receptor  (sIL6R) proteins were purchased from R and D Systems (Abingdon, UK).  
 
Cell Culture  
Stably transfected Human Embryonic Kidney (HEK293T) cells, expressing 3xFlag-myc-
CMV-26 vector (Sigma-Aldrich, UK) containing full-length human EPAC1, as described 
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[39, 40], were grown in Dulbecco's modified Eagle's medium (DMEM), 10% (v/v) foetal 
bovine serum (Sigma-Aldrich, UK), 1% (v/v) of GlutaMAX supplement  (Sigma-Aldrich, 
UK) and 1% (v/v) penicillin/streptomycin (Sigma-Aldrich, UK) and incubated at 37°C in 5% 
(v/v) CO2. Selection of stable cell lines was maintained by addition of 1 mg/ml G418 (Sigma-
Aldrich, UK) to the growth medium. The human monocytic cell line THP-1 was cultured in 
RPMI 1640 medium (Fisher Scientific, UK) containing 10% (v/v) foetal bovine serum 
(Sigma-Aldrich, UK), 1% (v/v) penicillin/streptomycin (Sigma-Aldrich, UK) and 2 mM 
glutamine at 37°C in 5% (v/v) CO2. HUVECs were grown in EGM2 (PromoCell) at 37°C 
and 5% (v/v) CO2. Cells were passaged weekly to a maximum of six passages. 
 
EPAC1 siRNA Procedures 
HUVECs were seeded at 70,000 – 100,000 cells per well of a 6-well culture plate and grown 
in 2 ml complete growth medium until 50-60% confluent. The EPAC1 siRNA (Qiagen 
FlexiTube Hs_RAPGEF3_5) or non-targeting siRNA (Qiagen AllStars Negative Control) 
was prepared for transfection by mixing 7 µl PromoFectin-HUVEC solution (Promocell) in 
100 µl serum-free culture medium with 12 µl siRNA (from 20 µM stock), also dissolved in 
100 µl serum-free medium, and then incubating for 20 minutes at room temperature. 
Following this, the cell culture medium was replaced with 0.9 ml fresh serum-free medium 
and the siRNA/PromoFectin-HUVEC solution (200 µl) was added dropwise, while gently 
shaking the plate, giving a final siRNA concentration of 200 nM. Cells were then incubated 
at 37°C in 5% (v/v) CO2 for 4 hours. After incubation, the medium was removed carefully by 
aspiration and then 2 ml of fresh complete growth medium was added, and cells were further 
incubated for 48 hours, after which experimental procedures were carried out. 
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Western Blotting 
For western blotting, cells were harvested by scraping directly into 150 μl of SDS-
polyacrylamide gel electrophoresis sample buffer [62.5 mM Tris-HCl, pH 6.8, 2% (w/v) 
SDS, 10% (v/v) glycerol, 10 mM DTT, and 0.01% (w/v) bromophenol blue]. Samples were 
mixed by vortexing, denaturated for 5 min at 95°C, separated on 10% or 12% (w/v) resolving 
gels and then electroblotted onto nitrocellulose membranes. Membranes were then blocked in 
5% (w/v) milk powder, or 5% (w/v) bovine serum albumin for phospho-specific antibodies, 
in Tris-buffered saline containing 0.1% (v/v) Tween 20. Blots were incubated in primary 
antibodies overnight at 4°C followed by appropriate horseradish peroxidase-conjugated 
secondary antibodies for 1 h at room temperature. Blots were then developed using 
SuperSignal™ West Pico Chemiluminescent Substrate and visualised using a Fusion FX7-
SPECTRA system (Vilber, Germany) fitted with a CCD camera. 
 
Immunoprecipitation of Active EPAC1 
HEK-293T cells transfected to overexpress EPAC1 [41] were cultured in 6-well plates in 
HUVEC growth medium (Promocell) or Dulbecco's modified Eagle's medium (DMEM), high 
glucose, supplemented with 10% (v/v) FBS, 1% (v/v) GlutaMAX, 1% (v/v) 
penicillin/streptomycin and 1 mg/ml G418 (to ensure selection of stable transfectants), 
respectively, until 90% confluence was reached. Cells were then stimulated for 30 min with 
either 50 µM 007 or 100 µM I942. After stimulation, cells were washed with ice cold 1x PBS 
and lysed in 1x RIPA buffer containing 1x protease inhibitor cocktail (Roche). The 
activation-selective EPAC1 mouse monoclonal antibody (5D3; 2 µl) [42, 43] was then added 
to the lysate and further incubated for 30 minutes (4°C, rotation). Following this, 10 µl of 
protein G magnetic beads (New England Biolabs) was added to antibody-containing lysates 
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followed by 1 hour further incubation at 4 °C with rotation. Protein G magnetic beads were 
then captured using a magnetic separation rack and then washed three times in 1x RIPA 
buffer. The beads were then resuspended in SDS-polyacrylamide gel electrophoresis sample 
buffer and boiled for 5 minutes before analysis by western blotting. 
 
Rap1 Activation Assay 
Detection of active GTP-bound Rap1 in EPAC1-expressing HEK293TT cells was done using 
an Active Rap1 Detection Kit (New England Biolabs, UK) according to the manufacturer’s 
instructions. Briefly, cells were grown to confluence in 10 cm culture dishes at 37°C in a 5% 
(v/v) CO2 incubator. Cells were then incubated with either I942 (100 M) or 007 (50 M) for 
15 min. Cells were then scrapped into 5 ml of 1x PBS, transferred to 15 ml centrifuge tubes 
and centrifuged at 800 x gmax for 3 min at room temperature. Cell pellets were then 
resuspended in 0.5 ml ice-cold lysis buffer containing 1 mM PMSF, transferred to Eppendorf 
tubes and then lysed by vortexing. Cell lysates were kept on ice for 5 min and then 
centrifuged at 16,000 x gmax at 4°C for 15 min. The supernatants were transferred to fresh 
Eppendorf tubes and used for GTPase assay (50 l of each cell lysate was left for analysis of 
total Rap1 content). GTPS and GDP-treated lysates were used as positive and negative 
controls for the assay, respectively, (Fig 1b). For the assay, cell lysates were incubated with 
100 l of 50% (w/v) glutathione-agarose beads and 20 g of GST-RalGDS-RBD (which 
selectively binds Rap1.GTP) on a spin column at 4°C for 1 h (with gentle rocking). The 
beads were harvested by centrifugation at 6,000 xg max for 30 seconds and washed three times 
in 1x lysis/binding/wash buffer. GTP-bound Rap1 proteins were eluted from pelleted beads 
by adding 50 l of 2x SDS Sample Buffer (containing 200 mM DTT) to the column followed 
by vortexing. Beads were then pelleted by centrifugation 6,000 x gmax for 2 min and eluted 
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samples were then heated for 5 min at 95°C and subjected to SDS-PAGE and western blot 
analysis with anti-Rap1 specific antibodies. 
 
mRNA Extraction 
HUVECs were grown on 6-well plates until they had achieved 70-80 % confluence. Cells 
were then incubated in the presence or absence of 50 M 007 for various times up to 48 
hours. Total RNA was then isolated from cells using an RNeasy Kit (Qiagen, Manchester, 
UK), according to the manufacturer’s protocol. RNA concentration was determined using 
NanoDrop Spectrophotometer (Thermo Fisher Scientific, Paisley, UK). Isolated total RNA 
was used for RNA sequencing and quantitative Real-Time PCR analysis.  
 
RNA Sequencing (RNAseq) 
Sequencing libraries were prepared from total RNA using the Illumina TruSeq Stranded 
mRNA Sample Preparation Kit. Libraries were sequenced in 75 base, paired end mode on the 
Illumina NextSeq 500 platform. Raw sequence reads were trimmed for contaminating 
sequence adapters and poor quality bases using the program Cutadapt1 [44]. Bases with an 
average Phred score lower than 28 were trimmed. Reads that were trimmed to less than 54 
bases were discarded. The quality of the reads was checked using the Fastqc program 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) before and after trimming. The 
reads were “pseudo aligned” to the transcriptome using the program Kallisto2 [45]. The 
differential expression for the analysis groups were assessed using the Bioconductor package 
DESeq23 [46]. Grouping of gene expression data into similarly responsive patterns was done 
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using Java TreeView and CLUSTER 3.0 [47], which are freely available online 
(http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm). 
 
Quantitative Real-Time PCR 
For reverse-transcription, 1 μg of total RNA was converted to first-strand cDNA using RT² 
First Strand Kit (Qiagen, UK) in accordance with the manufacturer's instructions. First, 
genomic DNA was eliminated using the buffer provided in the kit (5 min at 42°C), followed 
by reverse-transcription reaction (15 min at 42°C followed by 5 min at 95°C). Real-Time 
PCR analysis was performed using the Qiagen Human Endothelial Cell Biology RT2 Profiler 
PCR Array (384-well format containing 4 x 96 PCR arrays) and RT² SYBR Green Mastermix 
(Qiagen, UK) using a 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific, UK), 
according to the manufacturer’s protocol. Each PCR Array included 89 validated qPCR 
Primers Assays, including 5 housekeeping genes and a control panel. The thermal cycling 
program was as follows: 10 min at 95°C for HotStart DNA Taq Polymerase activation, 40 
cycles of denaturation at 95°C for 15 s and annealing and extension at 60°C for 1 min. Each 
experiment was run in triplicate. Data analysis and quantification of relative mRNA gene 
expression were performed by the CT method using free PCR Array Data Analysis Web 
portal at http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php.  
 
Monocyte Adhesion Assay 
Adhesion Assays were performed using Endothelial Cell Adhesion Assay Kit (Chemicon). 
HUVEC cells were seeded on 96-well plates at 104 cells per well and incubated at 37°C and 
5% (v/v) CO2 overnight. The next day cells were pre-treated with I942 (100 M) for 30 min 
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followed by 48 hrs treatment with IL6/sIL6Rα. After the treatment HUVECs were incubated 
with blocking monoclonal antibodies against SELE, VCAM1, ICAM1 or control mouse IgG 
(10 g/ml) for 1 hour and then the cell adhesion assay was performed. THP-1 monocytes 
were labelled with the fluorescent dye calcein AM (5 M) for 30 min, washed 3 times with 
PBS and resuspended in 5 ml of Assay Buffer. Cells were counted and diluted to a 
concentration of 2 x 106 cells/ml. Calcein AM-labelled THP-1 cells were added (106 cells/ml) 
to monolayers of HUVECs and incubated for 1 hr at 37°C in 5% (v/v) CO2. Non-adherent 
THP-1 cells were washed off with 3 times gentle washing with assay buffer. Monocyte 
adhesion was measured using a fluorometer with excitation and emission filters set to 494 
and 517 nm, respectively.  
 
Densitometry and Statistical Analysis 
Non-saturated immunoblots from multiple experiments (n=3) were quantified 
densitometrically using ImageJ software (http://rsbweb.nih.gov/ij/). Statistical significance 
was determined by one-way ANOVA with Tukey post-hoc test, using InStat Software 
(GraphPad Software, San Diego, CA).  
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Results 
I942 induces cellular EPAC1 activity and Rap1 activation in HEK293T cells 
We have previously shown that the EPAC1/Rap1 pathway mediates the induction of the 
SOCS3 gene in HUVECs, independently of PKA activation [48, 49]. To confirm that the 
recently identified EPAC1 agonist, I942 [38], is also able to activate the EPAC1/Rap1 
pathway in cells we performed EPAC1 and Rap1 activation assays in HEK293T cells stably 
expressing EPAC1 (HEK293T-EPAC1) [39] (Fig 1). First, HEK293T-EPAC1 cells were 
stimulated with the EPAC1-selective cAMP analogue 8-pCPT-2'-O-Me-cAMP (007) [50] or 
I942 and then cell extracts were immunoprecipitated with the activation-selective EPAC1 
monoclonal antibody, 5D3 [40, 42], which has been shown to interact with active EPAC1 in 
these cells [40] (Fig 1a). Both 007 and I942 treatment were found to promote a significant 
increase in EPAC1 activation in HEK293T-EPAC1 cells, as illustrated by an increase in the 
amount of immunoprecipitated EPAC1 from stimulated cells (Fig 1a), demonstrating for the 
first time that I942 exerts agonist activity towards cellular EPAC1. 
 
We next examined whether EPAC1 activation by I942 is sufficient to activate Rap1 in 
HEK293T-EPAC1 cells (Fig 1b). Active, GTP-bound Rap1 (Rap1.GTP) was isolated from 
cell extracts by pull-down with a GST-tagged recombinant version of the Rap1-binding 
domain (RBD) of the protein RalGDS, which selectively interacts with Rap1.GTP [51]. 
Following pull-down with GSH-agarose, samples were boiled in SDS sample buffer and the 
amount of isolated Rap1.GTP was estimated by western blotting with an anti-Rap1 antibody 
(Fig 1b). Initial experiments demonstrated that maximal activation of Rap1 occurred 
following 15 minutes stimulation with 007 (Fig 1b, lower panel), achieving levels roughly 
equivalent to those achieved by GTPS-stimulation of cell extracts, which represents 
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maximal Rap1 activation by this assay (Fig 1b, upper panel). Using this protocol, we 
observed a modest, but significant increase in Rap1 activation after 15 min treatment with 
100 M I942 (Fig 1c), which represented around 25% of maximal Rap1 activation by 007, 
indicating that EPAC1 activation by I942 is able to stimulate Rap1 activity in these cells. 
 
I942 promotes EPAC1-dependent SOCS3 induction and inhibition of IL6 signalling in 
HUVECs 
Having demonstrated that I942 exerts agonist activity in HEK293T-EPAC1 cells we wished 
to explore whether I942 can regulate down-stream signalling from EPAC1 and Rap1 in 
HUVECs. We have tried to measure Rap1 and EPAC1 activation in HUVECs using 
standard assays, but the relative expression levels of both proteins in these cells are so 
low that it is not technically feasible to detect activation, even with very potent stimuli. 
However, we have previously shown that activation of EPAC1 in HUVECs, which express 
EPAC1 but not EPAC2 [52], leads to the induction of the SOCS3 gene through the activation 
of Rap1, which induces C/EBP transcription factor binding to a key AP1 consensus site in the 
SOCS3 minimal promoter [48, 49, 53, 54]. We therefore stimulated HUVECs with I942, the 
Gs-coupled receptor peptide agonist, adrenomedullin 2 (ADM2) [55], rolipram, to inhibit 
endogenous type 4 cAMP phosphodiesterase activity, or forskolin, to promote adenylate 
cyclase activation, in the presence of the proteasome inhibitor MG132 to prevent the 
normally rapid breakdown of SOCS3 protein in cells following its synthesis [56, 57] (Fig 2a). 
We found that I942 treatment of HUVECs promoted a significant increase in SOCS3 
induction and potentiated SOCS3 induction by ADM2 and rolipram, but not forskolin (Fig 
2a). This indicates that I942 activates the same cyclic AMP signalling pathways induced by 
activation endogenous cyclic AMP signalling systems, as induced by ADM2 and rolipram. 
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Presumably, the high levels of cyclic AMP induced by forskolin treatment induce maximal 
activation of EPAC1 and SOCS3 induction, and are therefore not stimulated further by co-
stimulation with I942. This is interesting because I942 was originally characterised as being a 
partial agonist, in that although I942 stimulates EPAC1 GEF activity using in vitro assays, it 
antagonised cyclic AMP-stimulated EPAC1 activity [38]. However, it should be pointed out 
that the in vitro concentrations of I942 and cyclic AMP used in these competition assays was 
very high (500 M), whereas 100 M I942, as used in the HUVEC experiments here, did 
promote a significant action of EPAC1 in vitro but not produce a significant inhibition of 
cyclic AMP-promoted GEF activity [38]. Therefore, in the cell experiments performed here 
we are able to observe solely the agonist properties of I942 on SOCS3 induction. 
To confirm that the induction of SOCS3 by I942 is reliant on EPAC1 activity, we used two 
methods to inhibit endogenous EPAC1, namely siRNA silencing and use of an EPAC1 
antagonist, ESI-09 (Fig 2b and 2c). We found that both EPAC1 siRNA and ESI-09 treatment 
significantly inhibited SOCS3 induction by I942 (Fig 2b and 2c), indicating that actions of 
I942 are dependent on EPAC1. Interestingly, we observed that while ESI-09 treatment 
completely inhibited I942-induced SOCS3, it did not completely inhibit SOCS3 induction by 
forskolin and rolipram (F/R), suggesting that the high levels of SOCS3 induction by F/R 
might also have a PKA component. Indeed, we found that treatment of F/R stimulated cells 
with the broad-spectrum PKA inhibitor, H-89 [58], to discriminate between EPAC1-
dependent and independent actions, partially inhibited SOCS3 induction by F/R (Fig 2c), 
suggesting that optimal SOCS3 induction may result from synergistic activation of both PKA 
and EPAC1. To confirm that H-89 inhibits PKA in HUVECs, cell extracts were also 
immunoblotted with antibodies towards the transcription factor CREB, which is 
phosphorylated by activated PKA on Serine 133 [59], and we found that H-89 effectively 
inhibited PKA in these cells (Fig 2c). Moreover, we also found that the remaining PKA-
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independent SOCS3 response, following H-89 treatment of F/R-stimulated cells, coincided 
with that elicited by I942 (Fig 2c) and therefore can be attributed to EPAC1 activation. 
Having determined that I942 can induce SOCS3 expression in an EPAC1-dependent manner 
in HUVECs, we next investigated whether this was able to affect JAK/STAT3 signalling 
activated by the IL6 receptor (Fig 3). In these experiments, HUVECs were stimulated with 
IL6, in the presence or absence of I942, for various times over a time-course of 48 hours, 
following which cell extracts were immunoblotted with anti-phospho-STAT3 antibodies (Fig 
3). We found that co-stimulation with IL6 and I942 caused a significant reduction in STAT3 
activation between 5 and  48 hours when compared to cells stimulated with IL6 alone for the 
same period (Fig 3). Together, these results demonstrate that I942 treatment of HUVECs 
leads to SOCS3 induction and inhibition of long-term JAK/STAT3 signalling induced by 
IL6. I942 therefore has the ability to inhibit pro-inflammatory gene expression evoked by 
JAK/STAT3 signalling in HUVECs. 
 
Identification of genes regulated by I942 in HUVECs 
Results suggest that EPAC1 activation by I942 has the potential to suppress the pro-
inflammatory gene expression through the inhibition of JAK/STAT3 signalling in HUVECs. 
However, the full range of genes regulated by EPAC1 has yet to be determined in VECs. To 
explore this further we aimed to identify EPAC1-regulated genes in HUVECs and determine 
their responsiveness to I942 treatment. We therefore performed RNA-sequencing (RNA-Seq) 
in HUVECs treated with 007, I942, F/R or a combination of F/R and I942 for 48 hrs 
(Supplementary Data File). From these reads, we identified 425 genes whose activity was 
significantly (p<0.05) altered following 48 hours 007 treatment and similarly regulated by 
I942 and F/R, the majority of which were downregulated by the treatments applied (Fig 4a, 
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blue cluster, and Supplementary Data File). We also found that many of the genes that were 
regulated similarly by 007, I942 and F/R were specifically involved in vascular function, 
including the genes for the cell adhesion molecules, VCAM1 and SELE, which were both 
downregulated and are involved in monocyte adhesion in VECs [11, 12] (Fig 4b; red arrows). 
To confirm these results we used Human Endothelial Cell Biology RT2 Profiler™ PCR 
Arrays to examine the expression of endothelial specific genes in HUVEC cells following 
007 treatment. The PCR probes included on the array represented candidate genes involved in 
functions such as inflammation, cell adhesion, platelet activation, angiogenesis, coagulation 
and apoptosis (Fig 4c). As with RNA-Seq experiments we found that treatment of HUVECs 
with 007 for 48 hours led to a general suppression of gene expression, although the majority 
of changes did not reach statistical significance (Fig 4c). However, we did find that 007 
provoked a significant decrease in the expression of VCAM1 and SELE, which we had 
previously identified by RNA-Seq as being amongst the genes exhibiting the largest fold 
suppression (Fig 4b).  
 
I942 suppresses VCAM1 protein expression in HUVECs 
Given that the expression of VCAM1 and SELE genes is significantly downregulated 
following EPAC1 activation by 007, I942 and F/R in HUVECs (Fig 4b), we next examined 
whether I942 could exert similar effects on VCAM1 and SELE protein levels. We also 
examined the expression of ICAM1 protein, since changes in its expression is often linked to 
inflammatory responses. We therefore treated HUVECs with IL6 over a time-course of 
stimulation up to 48 hours, in the presence or absence of I942. Cell extracts were then 
prepared and immunoblotted with antibodies recognising the adhesion molecules ICAM1, 
VCAM1 and SELE (Fig 5a). We found that IL6 treatment led to a robust induction of 
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ICAM1 and VCAM1 protein expression at 48 hours, but exerted little effect on SELE 
expression (Fig 5a and 5b). Co-incubation with IL6 plus I942 led to a significant reduction in 
the expression of VCAM1 and SELE, but not ICAM1, in IL6-treated cells (Fig 5b). We 
confirmed an involvement of EPAC1 activation in the suppression of VCAM1 protein levels 
by stimulating cells with I942, 007 and F/R for 48 hours, in the presence or absence of IL6 
(Fig 5c). This led to a general suppression of VCAM1 protein expression both in the presence 
and absence of IL6, indicating a negative regulatory role for EPAC1 in the basal control of 
VCAM1 expression in HUVECs. To determine whether the regulation of expression of 
VCAM1 or SELE by I942 and 007 can influence the attachment of monocytes to HUVECs, 
we stimulated cells for 48 hours with IL6 in the presence or absence of I942 or 007 and 
determined the ability of THP-1 monocytes to attach to HUVEC monolayers (Fig 5d). 
Monoclonal blocking antibodies against ICAM1, VCAM1 and SELE were also used to 
determine their individual roles in promoting monocyte adhesion (Fig 6a). Results 
demonstrated that IL6 promoted a significant recruitment of monocytes to HUVEC 
monolayers. This was blocked by co-incubation with ICAM1, VCAM1 and SELE antibodies 
(Fig 6a). We also found that co-incubation with either I942 or 007 suppressed IL-6 driven 
monocyte adhesion (Fig 6b). Given that I942 and 007 suppresses VCAM1 protein expression 
(Fig 5c), this suggests that EPAC1 regulates monocyte adhesion through downregulation of 
the VCAM1 gene in VE s. 
Although these experiments indicate that both I942 and 007 can inhibit IL6-promoted 
monocyte adhesion to HUVECs, which correlates with inhibition of VCAM1 expression by 
both these agents (Fig 5c), it is unclear as to whether suppression of VCAM1 expression is 
sufficient to block monocyte adhesion in these cells. To test this we examined the role of 
VCAM1 in TNF-mediated monocyte adhesion and found that inhibition of VCAM1 with 
blocking antibodies is sufficient to inhibit TNF-mediated monocyte adhesion in HUVECs 
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(Fig 6c). Moreover, we found that I942 treatment significantly inhibited TNF-mediated 
monocyte adhesion, presumably through inhibition of VCAM1 expression. 
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Discussion 
Our aim has been to develop potent, small molecule selective regulators of EPAC1 activity to 
determine the role of EPAC1 in the control of vascular inflammation and cardiovascular 
disease by cyclic AMP. To date, high throughput screening (HTS) of compound libraries to 
search for small molecule regulators of EPAC activity [60-63] has led to the discovery of the 
EPAC2-selective inhibitor, ESI-05 [64] and a non-selective EPAC1 and EPAC2 inhibitor, 
ESI-09  [65-67]. Subsequently, uncompetitive (CE3F4) and non-competitive EPAC1 
inhibitors (5225554 and 5376753) have also been identified through HTS using an in vitro 
EPAC1 GEF activity assay [61] and an EPAC-based bioluminescence resonance energy 
transfer-based assay [60], respectively. Notably, only two selective cyclic nucleotide derived 
EPAC agonists have been developed, namely the EPAC1 selective agonist, 007 [68], and the 
EPAC2 agonist, S-220 [68]. Unfortunately, the practical use of S-220 in vivo is limited, since 
activation of EPAC2, but not EPAC1, causes arrhythmia and reduced cardiac function in 
animal models [69, 70]. and Moreover, 007 has limited cell permeability and potency in vivo. 
There is therefore a pressing need to develop further non-cyclic nucleotide EPAC1-directed 
agonists in order to fully define the role of EPAC1 in the development of CVD. 
To address this, we previously carried out HTS of a 5000 compound, small molecule library 
to isolate ligands targeting the CNBD of EPAC1 [38]. After triage, using microscale 
thermophoresis (MST), we identified a range of small molecule competitors of cAMP 
binding to EPAC1, with potencies similar to that of cAMP (pIC50=5.5). Subsequently, ligand 
observed nuclear magnetic resonance (NMR) analysis demonstrated direct interaction 
between inhibitor I942 and the CNBD of EPAC1 [38]. We also found that I942 effectively 
promotes EPAC1, but not EPAC2, activity in vitro [38], but we had yet to determine the 
cellular actions of this compound. Here, for the first time, we demonstrate that I942 has the 
ability to provoke EPAC1 activation in HEK293T cells expressing EPAC1, using activation-
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specific EPAC1 antibodies and Rap1 activation assays (Fig 1). I942 therefore represents an 
effective tool to probe the function of cellular EPAC1. In this regard, and consistent with our 
previous observations that activation of EPAC1 is sufficient to induce SOCS3 gene activity 
[49, 53, 54], we found that I942 promotes SOCS3 protein induction in an EPAC1-dependent 
manner (Fig 2b and 2c) as well as inhibiting IL6-promoted STAT3 activity. Activation of 
EPAC1 by I942 therefore has the potential ability to regulate gene expression both in the 
short-term and long-term. In the case of the SOCS3 gene, there are direct effects on 
transcription factor recruitment to the gene promoter between 30 minutes and 5 hours [49, 
54], whereas, in the long-term, I942 inhibits STAT3 signalling between 5 and 48 hours (Fig 
3). One caveat does remain however, in that we have tried to measure Rap1 and EPAC1 
activation in HUVECs using standard assays, but the relative expression levels of both 
proteins in these cells are so low that it is not technically feasible to detect activation, even 
with very potent stimuli. Future work should therefore be directed to determining any off-
target effects of I942 in these cells, since, at this stage, we cannot equivalently state that 
induction of SOCS3 and suppression of STAT3 activation are wholly due to I942 effects in 
these cells. 
In the present study, we have found that treatment of HUVECs with I942 leads to alterations 
in the expression of a wide variety of genes, many of which are associated with vascular 
function. In particular, we demonstrate that both 007 and I942 suppress the expression of the 
pro-inflammatory adhesion molecule, VCAM1, at the protein and mRNA level. This is 
consistent with previous work demonstrating that the PDE4 inhibitor, roflumilast, inhibits 
neointimal hyperplasia and VCAM1 expression in an EPAC1 dependent manner in vascular 
smooth muscle cells [71] and that the cyclic AMP-elevating drugs, forskolin and IBMX, 
suppress the expression of VCAM1 in HUVECs [72], although the molecular mechanisms 
underlying these effects remain to be determined. However, given that the IL6-activated 
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JAK/STAT3 pathway leads to the upregulation of VCAM1 expression in human aortic 
endothelial cells (HAECs) [18], it is tempting to speculate that inhibition of JAK/STAT3 
signalling by 007 [56] or I942, as reported here (Fig 3), may play a role in regulating 
VCAM1 expression.  However, regulation of other transcription pathways in addition to 
JAK/STAT3 signalling may underlie the actions of I942 on the expression of cell adhesion 
molecules. In this regard, the VCAM1 gene promoter contains binding sites for a number of 
transcription factors, including NF-κB and AP-1, both of which can be activated by IL6 [73-
75]. AP-1 transcription binding sites can bind C/EBP and c-Jun transcription factors, both of 
which we have shown to be important for SOCS3 gene induction by EPAC1 [49, 53, 54]. 
Equally, it has been known for some time that cyclic AMP inhibits NF-κB activation in a 
variety of cell backgrounds, including endothelial cells [76-79], but the role of EPAC1 in the 
regulation of NF-κB remains to be determined since it has been reported to serve as an 
activator of NF-κB signalling [80, 81]. Clearly, further work will be necessary to determine 
the molecular mechanisms underlying the actions of I942 on adhesion molecule expression in 
VECs. However, it is nevertheless clear that I942 represents a valuable tool for probing the 
actions of EPAC1 in vascular function. I942 therefore represents the first non-cyclic 
nucleotide EPAC1 agonist with the potential to exert anti-inflammatory actions in VECs. 
Indeed, this work contributes to the case justifying an exploration of EPAC1 activators, based 
on the starting structure of I942, as agents for suppression of vascular inflammation and neo-
intimal hyperplasia and promotion of re-endothelialisation following percutaneous coronary 
intervention procedures, where EPAC1 appears to play a key role.  
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Figure Legends 
Figure 1 The Novel EPAC1 Ligand, I942, Activates EPAC1 and Rap1 in HEK293T 
Cells 
a) EPAC1-expressing HEK293TT (HEK293T-EPAC1) cells were incubated with either 
I942 (100 M) or 007 (50 M) for 30 min and then cell extracts were 
immunoprecipitated with the anti-EPAC1 antibody, 5D3, which selectively interacts 
with the active form of EPAC1. The amount of immunoprecipitated, active EPAC1 in 
cell extracts was determined by western blotting with the 5D3 antibody (upper panel), 
with increased EPAC1 immunoreactivity indicating an increase in cellular EPAC1 
activation. Multiple western blots were analysed by densitometry and the results are 
displayed as a histogram of means ± S.E.M. in the lower panel. Significant increases 
in EPAC1 activity, relative to diluent-treated control cells, are indicated; **, p<0.01 
and ***, p<0.001, respectively (n=3). 
b) Active Rap1 was isolated from HEK293T-EPAC1 cell extracts stimulated with either 
GDP or GTPS using affinity purification columns as described in Materials and 
Methods. The amount of purified active Rap1 in stimulated samples was determined 
by western blotting with an anti-Rap1 antibody (upper panel). In the lower panel, 
HEK293T-EPAC1 cells were stimulated for the indicated time with 007 (50 M) and 
then active, Rap1.GTP, was isolated from cell extracts as described in Materials and 
Methods. 
c) HEK293T-EPAC1 cells were incubated with either I942 (100 M) or 007 (50 M) 
for 30 min and then Rap1.GTP was isolated from cell extracts using affinity 
purification columns and visualised by immunoblotting with an anti-Rap1 antibody as 
described in Materials and Methods. Multiple western blots were analysed by 
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densitometry and the results are displayed as a histogram of means ± S.E.M. in the 
lower panel. Significant increases in Rap1 activity, relative to diluent-treated control 
cells, are indicated; *, p<0.05 and ***, p<0.001, respectively (n=4). 
 
Figure 2 I942 Activates EPAC1-dependent Signalling in HUVECs 
a) HUVECs were stimulated for 5 hours with the indicated combinations of 10 M 
forskolin, 10 M rolipram, 100 nM ADM2 and 100 M I942 in the presence 10 M 
MG132. Cell extracts were then prepared and immunoblotted with anti-SOCS3 and 
anti-GAPDH antibodies. The histogram in the lower panel demonstrates changes in 
SOCS3 expression relative to control cells for three separate experiments. Significant 
increases in SOCS3 protein expression in I942-treated cells are indicated; ***, 
p<0.001 (n=3). Non-significant changes in SOCS3 immunoreactivity in cells treated 
with I942 and forskolin are also indicated (ns). 
b) Confluent HUVECs were pre-incubated with siRNA to EPAC1 or non-targeting, 
scrambled siRNA for 24 hours, after which cells were treated with the proteasome 
inhibitor, 10 M MG132 (to prevent breakdown of cellular SOCS3 protein), and then 
stimulated for 5 hours in the presence or absence of 100 M I942. Cell extracts were 
then prepared and immunoblotted with antibodies to SOCS3 protein, EPAC1 and 
GAPDH, as a loading control. Densitometry was then carried out on 3 western blots 
and results are shown as a histogram in the lower panel. Significant increases in 
SOCS3 protein expression, relative to diluent-stimulated control cells, are indicated; 
***, p<0.001. Significant inhibition of SOCS induction relative to I942-treated cells 
is also indicated; ###, p<0.001. 
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c) HUVECs were preincubated for 30 minutes with the EPAC1 antagonist, ESI-09 (10 
M) or the broad-spectrum protein kinase A (PKA) inhibitor, H89 (10 M), and then 
stimulated for a further 5 hours with either 100 M I942 or a combination of 10 M 
forskolin and 10 M rolipram (F/R) in the presence 10 M MG132. Cell extracts 
were then prepared and immunoblotted with either the PKA substrate phospho-
protein, CREB (pSer133), anti-SOCS3 and anti-GAPDH antibodies, respectively. 
Densitometry of SOCS3 expression from 3 separate experiments is shown in a 
histogram in the lower panel. Significant increases in SOCS3 expression relative to 
control cells are indicated, ***, p<0.001, as are non-signifcant changes (ns). 
 
Figure 3 I942 inhibits IL6-promoted JAK/STAT3 Signalling in HUVECs 
In the upper panel HUVECs were pre-incubated with 100 M I942 for 30 min and then 
incubated with IL6 (5 ng/ml) plus sIL6Rα (25 ng/ml) for different periods of time up to 48 
hrs. Cell extracts were then prepared and immunoblotted with antibodies to phosphorylated 
and non-phosphorylated STAT3. Densitometric values from 3 separate immunoblots are 
shown in the lower panel with significant decreases in STAT3 phosphorylation being 
indicated, ###, p<0.001, relative to IL6-stimulated cells. 
 
Figure 4 I942 promotes global changes in gene expression in HUVECs 
a) In order to identify genes regulated by I942, confluent HUVECs were stimulated for 
the indicated times with 50 M 007, 100 M I942, F/R or F/R plus 100 M I942. 
Total RNA was then extracted from cells and processed for RNAseq as described in 
Materials and Methods. The resulting data was subjected to CLUSTER analysis to 
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generate a dendrogram (on the left) to group together gene changes with similar 
expression profiles.  This identified a group of 425 genes that are either significantly 
(p<0.05; n=4) induced (yellow) or repressed (blue) following treatment. The colour 
key indicates the relative fold change in gene expression. 
b) The RNAseq data generated for Figure 5a was re-analysed to identify gene expression 
changes that are specifically associated with endothelial function. Red arrows 
indicated the expression changes for VCAM1 and SELE cell adhesion genes that were 
strongly suppressed by 007 treatment. 
c) HUVECs were stimulated for 48 hours with 50 M 007 and then total cell RNA was 
extracted and subjected to RT-PCR using a RT² Profiler™ PCR Array for Human 
Endothelial Cell Biology as described in Materials and Methods. The histogram 
shows fold changes in gene expression of a range of selected genes that were either 
up-regulated (yellow) or down-regulated (blue). Significant changes in gene 
expression are indicated; #, p<0.05 and ##, p<0.01 (n=4). The dotted red line indicates 
gene expression changes that did not achieve significance. 
 
Figure 5 Effects of I942 on the Expression of ICAM1, VCAM1 and SELE in 
HUVECs 
a) HUVECs were stimulated for the indicated times with IL6 (5 ng/ml) plus sIL6Rα (25 
ng/ml), in the presence or absence of 100 M I942. Cell extracts were then prepared 
and immunoblotted with antibodies that recognise ICAM1, VCAM1, SELE and 
GAPDH. 
b) Densitometric values from three independent experiments from Fig 3a are shown as a 
chart of means ± S.E.M. (n=3). Significant increases or decreases in protein 
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expression, relative to cells stimulated with IL6 alone are indicated (*, p<0.05 and **, 
p<0.01 or #, p<0.05 ##, p<0.01 and  ###, <0.001 respectively). 
c) HUVECs were stimulated for 48 hours with either 100 M I942, 50 M 007 or 10 
M forskolin plus 10 M rolipram (F/R) in the presence or absence of IL6 (5 ng/ml) 
plus sIL6Rα (25 ng/ml). Cell extracts were then immunoblotted with antibodies to 
VCAM1 or GAPDH, as indicated. Densitometric values from 3 separate immunoblots 
are shown in the lower panel with significant increases in VCAM1 expression in cells 
stimulated with IL6 being indicated; *, p<0.05. Significant decreases in VCAM1 
expression relative to cells stimulated with IL6 alone are also indicated ###, p<0.001. 
Non-significant changes are also indicated (ns). 
 
Figure 6 I942 Inhibits Monocyte adhesion to HUVEC Monolayers 
a) Confluent HUVEC monolayers were stimulated for 48 hours with IL6 (5 ng/ml) plus 
sIL6Rα (25 ng/ml) in the presence or absence of blocking antibodies to ICAM1,  
VCAM1 and SELE. Monolayers were then incubated with fluorescently labelled 
monocytes and the amount of monocyte attachment to monolayers was calculated 
using a fluorometer, as described in Materials and Methods. The relative degree of 
monocyte adhesion is with significant increases in adhesion being indicated, *, 
p<0.05, and significant decreases in adhesion relative to IL6 treated cells with control 
antibody are also indicated #, p<0.05 (n=3). Images of adherent monocytes are shown 
in the lower panel. 
b) HUVECs were stimulated with IL6 (5 ng/ml) plus sIL6Rα (25 ng/ml) in the presence 
or absence of 100 M I942 or 50 M 007. Increases in monocyte adhesion are 
indicated, *, p<0.05, as are significant decreases relative to IL6-stimulated cells, #, 
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p<0.05 and ###, p<0.001 (n=3). Non-significant changes are also indicated (ns). 
Images of adherent monocytes are shown in the lower panel. 
c) In the upper panel, confluent HUVEC monolayers were stimulated for 48 hours with 
TNF (10 ng/ml) in the presence or absence of blocking antibodies to ICAM1, 
VCAM1 and SELE. Monolayers were then incubated with fluorescently labelled 
monocytes and the amount of monocyte attachment to monolayers was calculated 
using a fluorometer, as described in Materials and Methods. The relative degree of 
monocyte adhesion is with significant increases in adhesion being indicated, **, 
p<0.01 and ***, p<0.001, and significant decreases in adhesion relative to TNF  
treated cells with control antibody are also indicated ###, p<0.001 (n=3). In the lower 
panel, HUVECs were TNF (10 ng/ml) for 5 hours in the presence or absence of 100 
M I942. Increases in monocyte adhesion are indicated, ###, p<0.001 (n=3), as are 
significant decreases relative to TNF -stimulated cells, ###, p<0.001.  
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
34 
 
References 
[1] L. Feng, C. Matsumoto, A. Schwartz, A.M. Schmidt, D.M. Stern, J. Pile-Spellman, 
Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-
PCR analysis, Diabetes care, 28 (2005) 379-384. 
[2] P.M. Ridker, N. Rifai, M.J. Stampfer, C.H. Hennekens, Plasma concentration of 
interleukin-6 and the risk of future myocardial infarction among apparently healthy men, 
Circulation, 101 (2000) 1767-1772. 
[3] T. Suzuki, S. Ishiwata, K. Hasegawa, K. Yamamoto, T. Yamazaki, Raised interleukin 6 
concentrations as a predictor of postangioplasty restenosis, Heart, 83 (2000) 578. 
[4] S.A. Brod, Unregulated inflammation shortens human functional longevity, Inflamm Res., 
49 (2000) 561-570. 
[5] D.A. Sukovich, K. Kauser, F.D. Shirley, V. DelVecchio, M. Halks-Miller, G.M. Rubanyi, 
Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: 
inhibition by 17beta-estradiol, Arteriosclerosis, thrombosis, and vascular biology, 18 (1998) 
1498-1505. 
[6] M. Shoji, F. Furuyama, Y. Yokota, Y. Omori, T. Sato, F. Tsunoda, Y. Iso, S. Koba, E. 
Geshi, T. Katagiri, H. Suzuki, Y. Kobayashi, IL-6 mobilizes bone marrow-derived cells to the 
vascular wall, resulting in neointima formation via inflammatory effects, J Atheroscler 
Thromb, 21 (2014) 304-312. 
[7] M. Naya, T. Tsukamoto, K. Morita, C. Katoh, T. Furumoto, S. Fujii, N. Tamaki, H. 
Tsutsui, Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary 
endothelial dysfunction in hypertensive patients, Hypertension research : official journal of 
the Japanese Society of Hypertension, 30 (2007) 541-548. 
[8] W. Zhang, W. Wang, H. Yu, Y. Zhang, Y. Dai, C. Ning, L. Tao, H. Sun, R.E. Kellems, 
M.R. Blackburn, Y. Xia, Interleukin 6 underlies angiotensin II-induced hypertension and 
chronic renal damage, Hypertension, 59 (2012) 136-144. 
[9] L.H. Wei, M.L. Kuo, C.A. Chen, C.H. Chou, K.B. Lai, C.N. Lee, C.Y. Hsieh, Interleukin-
6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway, 
Oncogene, 22 (2003) 1517-1527. 
[10] M. Jougasaki, T. Ichiki, Y. Takenoshita, M. Setoguchi, Statins suppress interleukin-6-
induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers 
and activators of transcription pathways in human vascular endothelial cells, British journal 
of pharmacology, 159 (2010) 1294-1303. 
[11] K. Ley, T.F. Tedder, Leukocyte interactions with vascular endothelium. New insights 
into selectin-mediated attachment and rolling, Journal of immunology (Baltimore, Md. : 
1950), 155 (1995) 525-528. 
[12] T. Collins, M.A. Read, A.S. Neish, M.Z. Whitley, D. Thanos, T. Maniatis, 
Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-
inducible enhancers, FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology, 9 (1995) 899-909. 
[13] D. Vestweber, Adhesion and signaling molecules controlling the transmigration of 
leukocytes through endothelium, Immunological reviews, 218 (2007) 178-196. 
[14] H.F. Langer, T. Chavakis, Leukocyte-endothelial interactions in inflammation, Journal 
of cellular and molecular medicine, 13 (2009) 1211-1220. 
[15] T. Hou, B.C. Tieu, S. Ray, A. Recinos Iii, R. Cui, R.G. Tilton, A.R. Brasier, Roles of IL-
6-gp130 Signaling in Vascular Inflammation, Curr Cardiol Rev., 4 (2008) 179-192. 
[16] H. Schuett, R. Oestreich, G.H. Waetzig, W. Annema, M. Luchtefeld, A. Hillmer, U. 
Bavendiek, J. von Felden, D. Divchev, T. Kempf, K.C. Wollert, D. Seegert, S. Rose-John, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
35 
 
U.J. Tietge, B. Schieffer, K. Grote, Transsignaling of interleukin-6 crucially contributes to 
atherosclerosis in mice, Arterioscler, 32 (2012) 281-290. . 
[17] M. Hashizume, N. Hayakawa, M. Suzuki, M. Mihara, IL-6/sIL-6R trans-signalling, but 
not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system, 
Rheumatology international, 29 (2009) 1449-1454. 
[18] Z. Wei, W. Jiang, H. Wang, H. Li, B. Tang, B. Liu, H. Jiang, X. Sun, The IL-6/STAT3 
pathway regulates adhesion molecules and cytoskeleton of endothelial cells in 
thromboangiitis obliterans, Cellular signalling, 44 (2018) 118-126. 
[19] K.J. Kim, S.H. Kwon, J.H. Yun, H.S. Jeong, H.R. Kim, E.H. Lee, S.K. Ye, C.H. Cho, 
STAT3 activation in endothelial cells is important for tumor metastasis via increased cell 
adhesion molecule expression, Oncogene, 36 (2017) 5445-5459. 
[20] A. Yoshimura, T. Naka, M. Kubo, SOCS proteins, cytokine signalling and immune 
regulation, Nat Rev Immunol., 7 (2007) 454-465. 
[21] J.C. Tan, R. Rabkin, Suppressors of cytokine signaling in health and disease, Pediatr 
Nephrol., 20 (2005) 567-575. 
[22] A. Sasaki, H. Yasukawa, A. Suzuki, S. Kamizono, T. Syoda, I. Kinjyo, M. Sasaki, J.A. 
Johnston, A. Yoshimura, Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus 
tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 
domain, Genes Cells., 4 (1999) 339-351. 
[23] X. Liang, M. He, T. Chen, Y. Liu, Y.L. Tian, Y.L. Wu, Y. Zhao, Y. Shen, Z.Y. Yuan, 
Multiple roles of SOCS proteins: differential expression of SOCS1 and SOCS3 in 
atherosclerosis, International journal of molecular medicine, 31 (2013) 1066-1074. 
[24] G. Ortiz-Munoz, J.L. Martin-Ventura, P. Hernandez-Vargas, B. Mallavia, V. Lopez-
Parra, O. Lopez-Franco, B. Munoz-Garcia, P. Fernandez-Vizarra, L. Ortega, J. Egido, C. 
Gomez-Guerrero, Suppressors of cytokine signaling modulate JAK/STAT-mediated cell 
responses during atherosclerosis, Arteriosclerosis, thrombosis, and vascular biology, 29 
(2009) 525-531. 
[25] B.A. Croker, H. Kiu, M. Pellegrini, J. Toe, S. Preston, D. Metcalf, J.A. O'Donnell, L.H. 
Cengia, K. McArthur, N.A. Nicola, W.S. Alexander, A.W. Roberts, IL-6 promotes acute and 
chronic inflammatory disease in the absence of SOCS3, Immunol Cell Biol, 90 (2012) 124-
129. 
[26] A. Stahl, J.S. Joyal, J. Chen, P. Sapieha, A.M. Juan, C.J. Hatton, D.T. Pei, C.G. Hurst, 
M.R. Seaward, N.M. Krah, R.J. Dennison, E.R. Greene, E. Boscolo, D. Panigrahy, L.E. 
Smith, SOCS3 is an endogenous inhibitor of pathologic angiogenesis, Blood, 120 (2012) 
2925-2929. 
[27] D. Jo, D. Liu, S. Yao, R.D. Collins, J. Hawiger, Intracellular protein therapy with 
SOCS3 inhibits inflammation and apoptosis, Nat Med., 11 (2005) 892-898. . 
[28] C. Recio, A. Oguiza, I. Lazaro, B. Mallavia, J. Egido, C. Gomez-Guerrero, Suppressor 
of cytokine signaling 1-derived Peptide inhibits janus kinase/signal transducers and activators 
of transcription pathway and improves inflammation and atherosclerosis in diabetic mice, 
Arteriosclerosis, thrombosis, and vascular biology, 34 (2014) 1953-1960. 
[29] S. Xiang, J. Liu, N. Dong, J. Shi, Y. Xiao, Y. Wang, X. Hu, L. Gong, W. Wang, 
Suppressor of cytokine signaling 3 is a negative regulator for neointimal hyperplasia of vein 
graft stenosis, Journal of vascular research, 51 (2014) 132-143. 
[30] S. Taleb, M. Romain, B. Ramkhelawon, C. Uyttenhove, G. Pasterkamp, O. Herbin, B. 
Esposito, N. Perez, H. Yasukawa, J. Van Snick, A. Yoshimura, A. Tedgui, Z. Mallat, Loss of 
SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis, 
The Journal of experimental medicine, 206 (2009) 2067-2077. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
36 
 
[31] E. Parnell, B.O. Smith, T.M. Palmer, A. Terrin, M. Zaccolo, S.J. Yarwood, Regulation 
of the inflammatory response of vascular endothelial cells by EPAC1, British journal of 
pharmacology, 166 (2012) 434-446. 
[32] E. Parnell, T.M. Palmer, S.J. Yarwood, The future of EPAC-targeted therapies: agonism 
versus antagonism, Trends in pharmacological sciences, 36 (2015) 203-214. 
[33] G. Barker, E. Parnell, B. van Basten, H. Buist, D.R. Adams, S.J. Yarwood, The Potential 
of a Novel Class of EPAC-Selective Agonists to Combat Cardiovascular Inflammation, 
Journal of cardiovascular development and disease, 4 (2017). 
[34] H. Kawasaki, G.M. Springett, N. Mochizuki, S. Toki, M. Nakaya, M. Matsuda, D.E. 
Housman, A.M. Graybiel, A family of cAMP-binding proteins that directly activate Rap1, 
Science, 282 (1998) 2275-2279. 
[35] J. de Rooij, F.J. Zwartkruis, M.H. Verheijen, R.H. Cool, S.M. Nijman, A. Wittinghofer, 
J.L. Bos, Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic 
AMP, Nature, 396 (1998) 474-477. 
[36] G. Borland, B.O. Smith, S.J. Yarwood, EPAC proteins transduce diverse cellular actions 
of cAMP, Br J Pharmacol., 158 (2009) 70-86. . 
[37] H. Jin, T. Fujita, M. Jin, R. Kurotani, Y. Hidaka, W. Cai, K. Suita, R. Prajapati, C. 
Liang, Y. Ohnuki, Y. Mototani, M. Umemura, U. Yokoyama, M. Sato, S. Okumura, Y. 
Ishikawa, Epac activation inhibits IL-6-induced cardiac myocyte dysfunction, The journal of 
physiological sciences : JPS, 68 (2018) 77-87. 
[38] E. Parnell, S.P. McElroy, J. Wiejak, G.L. Baillie, A. Porter, D.R. Adams, H. Rehmann, 
B.O. Smith, S.J. Yarwood, Identification of a Novel, Small Molecule Partial Agonist for the 
Cyclic AMP Sensor, EPAC1, Scientific reports, 7 (2017) 294. 
[39] E. Parnell, A. Koschinski, M. Zaccolo, R.T. Cameron, G.S. Baillie, G.L. Baillie, A. 
Porter, S.P. McElroy, S.J. Yarwood, Phosphorylation of ezrin on Thr567 is required for the 
synergistic activation of cell spreading by EPAC1 and protein kinase A in HEK293TT cells, 
Biochimica et biophysica acta, 1853 (2015) 1749-1758. 
[40] E. Parnell, B.O. Smith, S.J. Yarwood, The cAMP sensors, EPAC1 and EPAC2, display 
distinct subcellular distributions despite sharing a common nuclear pore localisation signal, 
Cellular signalling, 27 (2015) 989-996. 
[41] E. Parnell, S.J. Yarwood, Interactions between Epac1 and ezrin in the control of 
endothelial barrier function, Biochemical Society transactions, 42 (2014) 274-278. 
[42] M. Gloerich, B. Ponsioen, M.J. Vliem, Z. Zhang, J. Zhao, M.R. Kooistra, L.S. Price, L. 
Ritsma, F.J. Zwartkruis, H. Rehmann, K. Jalink, J.L. Bos, Spatial regulation of cyclic AMP-
Epac1 signaling in cell adhesion by ERM proteins, Molecular and cellular biology, 30 (2010) 
5421-5431. 
[43] E. Parnell, B.O. Smith, S.J. Yarwood, The cAMP sensors, EPAC1 and EPAC2, display 
distinct subcellular distributions despite sharing a common nuclear pore localisation signal, 
Cellular signalling, 27 (2015) 989-996. 
[44] M. Martin, Cutadapt removes adapter sequences from high-throughput sequencing reads, 
2011, 17 (2011). 
[45] N.L. Bray, H. Pimentel, P. Melsted, L. Pachter, Near-optimal probabilistic RNA-seq 
quantification, Nature biotechnology, 34 (2016) 525-527. 
[46] M.I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for 
RNA-seq data with DESeq2, Genome biology, 15 (2014) 550. 
[47] M.B. Eisen, P.T. Spellman, P.O. Brown, D. Botstein, Cluster analysis and display of 
genome-wide expression patterns, Proc Natl Acad Sci U S A., 95 (1998) 14863-14868. 
[48] G. Borland, R.J. Bird, T.M. Palmer, S.J. Yarwood, Activation of protein kinase Calpha 
by EPAC1 is required for the ERK- and CCAAT/enhancer-binding protein beta-dependent 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
37 
 
induction of the SOCS-3 gene by cyclic AMP in COS1 cells, J Biol Chem., 284 (2009) 
17391-17403. . 
[49] S.J. Yarwood, G. Borland, W.A. Sands, T.M. Palmer, Identification of 
CCAAT/enhancer-binding proteins as exchange protein activated by cAMP-activated 
transcription factors that mediate the induction of the SOCS-3 gene, J Biol Chem., 283 
(2008) 6843-6853. 
[50] J.M. Enserink, A.E. Christensen, J. de Rooij, M. van Triest, F. Schwede, H.G. Genieser, 
S.O. Doskeland, J.L. Blank, J.L. Bos, A novel Epac-specific cAMP analogue demonstrates 
independent regulation of Rap1 and ERK, Nature cell biology, 4 (2002) 901-906. 
[51] I. McPhee, M.D. Houslay, S.J. Yarwood, Use of an activation-specific probe to show 
that Rap1A and Rap1B display different sensitivities to activation by forskolin in rat1 cells, 
FEBS letters, 477 (2000) 213-218. 
[52] H.D. Woolson, V.S. Thomson, C. Rutherford, S.J. Yarwood, T.M. Palmer, Selective 
inhibition of cytokine-activated extracellular signal-regulated kinase by cyclic AMP via 
Epac1-dependent induction of suppressor of cytokine signalling-3, Cell Signal., 21 (2009) 
1706-1715. 
[53] J. Wiejak, J. Dunlop, S. Gao, G. Borland, S.J. Yarwood, Extracellular signal-regulated 
kinase mitogen-activated protein kinase-dependent SOCS-3 gene induction requires c-Jun, 
signal transducer and activator of transcription 3, and specificity protein 3 transcription 
factors, Mol Pharmacol., 81 (2012) 657-668. . 
[54] J. Wiejak, J. Dunlop, S.J. Yarwood, The role of c-Jun in controlling the EPAC1-
dependent induction of the SOCS3 gene in HUVECs, FEBS letters, 588 (2014) 1556-1561. 
[55] M. Aslam, U. Pfeil, D. Gunduz, A. Rafiq, W. Kummer, H.M. Piper, T. Noll, Intermedin 
(adrenomedullin2) stabilizes the endothelial barrier and antagonizes thrombin-induced barrier 
failure in endothelial cell monolayers, British journal of pharmacology, 165 (2012) 208-222. 
[56] W.A. Sands, H.D. Woolson, G.R. Milne, C. Rutherford, T.M. Palmer, Exchange protein 
activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 
(SOCS-3) in vascular endothelial cells, Molecular and cellular biology, 26 (2006) 6333-6346. 
[57] J.J. Williams, K.M. Munro, T.M. Palmer, Role of Ubiquitylation in Controlling 
Suppressor of Cytokine Signalling 3 (SOCS3) Function and Expression, Cells, 3 (2014) 546-
562. 
[58] T. Chijiwa, A. Mishima, M. Hagiwara, M. Sano, K. Hayashi, T. Inoue, K. Naito, T. 
Toshioka, H. Hidaka, Inhibition of forskolin-induced neurite outgrowth and protein 
phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein 
kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D 
pheochromocytoma cells, The Journal of biological chemistry, 265 (1990) 5267-5272. 
[59] G.A. Gonzalez, M.R. Montminy, Cyclic AMP stimulates somatostatin gene transcription 
by phosphorylation of CREB at serine 133, Cell, 59 (1989) 675-680. 
[60] L.M. Brown, K.E. Rogers, N. Aroonsakool, J.A. McCammon, P.A. Insel, Allosteric 
inhibition of Epac: computational modeling and experimental validation to identify allosteric 
sites and inhibitors, The Journal of biological chemistry, 289 (2014) 29148-29157. 
[61] D. Courilleau, M. Bisserier, J.C. Jullian, A. Lucas, P. Bouyssou, R. Fischmeister, J.P. 
Blondeau, F. Lezoualc'h, Identification of a tetrahydroquinoline analog as a pharmacological 
inhibitor of the cAMP-binding protein Epac, The Journal of biological chemistry, 287 (2012) 
44192-44202. 
[62] T. Tsalkova, F.C. Mei, S. Li, O.G. Chepurny, C.A. Leech, T. Liu, G.G. Holz, V.L. 
Woods, Jr., X. Cheng, Isoform-specific antagonists of exchange proteins directly activated by 
cAMP, Proceedings of the National Academy of Sciences of the United States of America, 
109 (2012) 18613-18618. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
38 
 
[63] I. McPhee, L.C. Gibson, J. Kewney, C. Darroch, P.A. Stevens, D. Spinks, A. Cooreman, 
S.J. MacKenzie, Cyclic nucleotide signalling: a molecular approach to drug discovery for 
Alzheimer's disease, Biochemical Society transactions, 33 (2005) 1330-1332. 
[64] T. Tsalkova, F.C. Mei, X. Cheng, A fluorescence-based high-throughput assay for the 
discovery of exchange protein directly activated by cyclic AMP (EPAC) antagonists, PloS 
one, 7 (2012) e30441. 
[65] M. Almahariq, T. Tsalkova, F.C. Mei, H. Chen, J. Zhou, S.K. Sastry, F. Schwede, X. 
Cheng, A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and 
invasion, Mol. Pharmacol., 83 (2013) 122-128. 
[66] H. Chen, T. Tsalkova, O.G. Chepurny, F.C. Mei, G.G. Holz, X. Cheng, J. Zhou, 
Identification and characterization of small molecules as potent and specific EPAC2 
antagonists, J. Med. Chem., 56 (2013) 952-962. 
[67] T. Tsalkova, F.C. Mei, S. Li, O.G. Chepurny, C.A. Leech, T. Liu, G.G. Holz, V.L. 
Woods, Jr., X. Cheng, Isoform-specific antagonists of exchange proteins directly activated by 
cAMP, Proc. Natl. Acad. Sci. U. S. A., 109 (2012) 18613-18618. 
[68] F. Schwede, D. Bertinetti, C.N. Langerijs, M.A. Hadders, H. Wienk, J.H. Ellenbroek, 
E.J. de Koning, J.L. Bos, F.W. Herberg, H.G. Genieser, R.A. Janssen, H. Rehmann, 
Structure-guided design of selective Epac1 and Epac2 agonists, PLoS biology, 13 (2015) 
e1002038. 
[69] Z. Yang, H. Kirton, M. Al-Owais, J. Thireau, S. Richard, D. Steele, C. Peers, Epac2-
Rap1 signaling regulates reactive oxygen species production and susceptibility to cardiac 
arrhythmias, Antioxidants & redox signaling, (2016). 
[70] L. Pereira, H. Cheng, D.H. Lao, L. Na, R.J. van Oort, J.H. Brown, X.H. Wehrens, J. 
Chen, D.M. Bers, Epac2 mediates cardiac beta1-adrenergic-dependent sarcoplasmic 
reticulum Ca2+ leak and arrhythmia, Circulation, 127 (2013) 913-922. 
[71] M. Lehrke, F. Kahles, A. Makowska, P.V. Tilstam, S. Diebold, J. Marx, R. Stohr, K. 
Hess, E.B. Endorf, D. Bruemmer, N. Marx, H.M. Findeisen, PDE4 inhibition reduces 
neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-
dependent manner, Journal of molecular and cellular cardiology, 81 (2015) 23-33. 
[72] J.S. Pober, M.R. Slowik, L.G. De Luca, A.J. Ritchie, Elevated cyclic AMP inhibits 
endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion 
molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1, 
Journal of immunology (Baltimore, Md. : 1950), 150 (1993) 5114-5123. 
[73] K.A. Roebuck, A. Finnegan, Regulation of intercellular adhesion molecule-1 (CD54) 
gene expression, Journal of leukocyte biology, 66 (1999) 876-888. 
[74] T. Minami, M.R. Abid, J. Zhang, G. King, T. Kodama, W.C. Aird, Thrombin stimulation 
of vascular adhesion molecule-1 in endothelial cells is mediated by protein kinase C (PKC)-
delta-NF-kappa B and PKC-zeta-GATA signaling pathways, The Journal of biological 
chemistry, 278 (2003) 6976-6984. 
[75] L. Wang, B. Walia, J. Evans, A.T. Gewirtz, D. Merlin, S.V. Sitaraman, IL-6 induces NF-
kappa B activation in the intestinal epithelia, Journal of immunology (Baltimore, Md. : 1950), 
171 (2003) 3194-3201. 
[76] V. Ollivier, G.C. Parry, R.R. Cobb, D. de Prost, N. Mackman, Elevated cyclic AMP 
inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells, 
The Journal of biological chemistry, 271 (1996) 20828-20835. 
[77] G.C. Parry, N. Mackman, Role of cyclic AMP response element-binding protein in 
cyclic AMP inhibition of NF-kappaB-mediated transcription, Journal of immunology 
(Baltimore, Md. : 1950), 159 (1997) 5450-5456. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
39 
 
[78] M. Ghosh, V. Aguirre, K. Wai, H. Felfly, W.D. Dietrich, D.D. Pearse, The interplay 
between cyclic AMP, MAPK, and NF-kappaB pathways in response to proinflammatory 
signals in microglia, BioMed research international, 2015 (2015) 308461. 
[79] A. Kim, M. Son, K.I. Kim, Y. Yang, E.Y. Song, H.G. Lee, J.S. Lim, Elevation of 
intracellular cyclic AMP inhibits NF-kappaB-mediated thymosin beta4 expression in 
melanoma cells, Experimental cell research, 315 (2009) 3325-3335. 
[80] E.Y. Moon, J.H. Lee, J.W. Lee, J.H. Song, S. Pyo, ROS/Epac1-mediated Rap1/NF-
kappaB activation is required for the expression of BAFF in Raw264.7 murine macrophages, 
Cellular signalling, 23 (2011) 1479-1488. 
[81] A. Mediero, M. Perez-Aso, B.N. Cronstein, Activation of EPAC1/2 is essential for 
osteoclast formation by modulating NFkappaB nuclear translocation and actin cytoskeleton 
rearrangements, FASEB journal : official publication of the Federation of American Societies 
for Experimental Biology, 28 (2014) 4901-4913. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
40 
 
Highlights 
 The novel EPAC1 ligand I942 activates cellular EPAC1 and Rap1 GTPase 
 I942 induces SOCS3 gene expression in vascular endothelial cells (VECs) 
 I942 suppresses JAK/STAT3 signalling from the IL6 receptor in VECs 
 I942 regulates 425 novel gene targets in VECs 
 I942 suppresses VCAM1 expression and monocyte adhesion in VECs  
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